OTCMKTS:ICOTF - iCo Therapeutics Stock Price, News & Analysis

$0.0910
0.00 (0.00 %)
(As of 09/20/2019 04:37 AM ET)
Today's Range
$0.0910
Now: $0.0910
$0.0910
50-Day Range
$0.0610
MA: $0.07
$0.1060
52-Week Range
$0.0290
Now: $0.0910
$0.1060
VolumeN/A
Average Volume10,982 shs
Market Capitalization$9.96 million
P/E RatioN/A
Dividend YieldN/A
Beta2.46
iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ICOTF
CUSIPN/A
CIKN/A
Phone778-802-9806

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.01) per share

Profitability

Net Income$-1,300,000.00

Miscellaneous

EmployeesN/A
Market Cap$9.96 million
Next Earnings Date12/5/2019 (Estimated)
OptionableNot Optionable

Receive ICOTF News and Ratings via Email

Sign-up to receive the latest news and ratings for ICOTF and its competitors with MarketBeat's FREE daily newsletter.


iCo Therapeutics (OTCMKTS:ICOTF) Frequently Asked Questions

What is iCo Therapeutics' stock symbol?

iCo Therapeutics trades on the OTCMKTS under the ticker symbol "ICOTF."

When is iCo Therapeutics' next earnings date?

iCo Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, December 5th 2019. View Earnings Estimates for iCo Therapeutics.

Has iCo Therapeutics been receiving favorable news coverage?

News headlines about ICOTF stock have been trending negative recently, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. iCo Therapeutics earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for iCo Therapeutics.

Who are some of iCo Therapeutics' key competitors?

What other stocks do shareholders of iCo Therapeutics own?

Who are iCo Therapeutics' key executives?

iCo Therapeutics' management team includes the folowing people:
  • Mr. Andrew J. Rae M.B.A., BSc, MBA, Co-Founder, CEO, Pres & Director (Age 52)
  • Mr. Michael Liggett CPA, CA, Bsc. Pharm., CFO, Corp. Sec. & Director (Age 59)
  • Dr. Peter Hnik M.D., MHSc, Chief Medical Officer (Age 63)

How do I buy shares of iCo Therapeutics?

Shares of ICOTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is iCo Therapeutics' stock price today?

One share of ICOTF stock can currently be purchased for approximately $0.0910.

How big of a company is iCo Therapeutics?

iCo Therapeutics has a market capitalization of $9.96 million. View Additional Information About iCo Therapeutics.

What is iCo Therapeutics' official website?

The official website for iCo Therapeutics is http://www.icotherapeutics.com/.

How can I contact iCo Therapeutics?

iCo Therapeutics' mailing address is 777 Hornby Street 6th Floor, Vancouver A1, V6Z 1S4. The biotechnology company can be reached via phone at 778-802-9806 or via email at [email protected]


MarketBeat Community Rating for iCo Therapeutics (OTCMKTS ICOTF)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  53 (Vote Underperform)
Total Votes:  110
MarketBeat's community ratings are surveys of what our community members think about iCo Therapeutics and other stocks. Vote "Outperform" if you believe ICOTF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICOTF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel